Medscape (June 16): Tirzepatide Reverses Postbariatric Weight Regain in University of Catania Study
A Medscape clinical study report June 16 from Federica Vinciguerra and colleagues at the University of Catania documented that tirzepatide reversed post-bariatric-surgery weight regain in patients several years out from sleeve gastrectomy or gastric bypass. Post-surgical weight regain affects roughly 50% of bariatric patients within 2-5 years; until recently, the field had no pharmacologic option that meaningfully reversed it. The Catania data add to the case that GLP-1 incretin therapy is a credible second-line option for the post-surgical regain population, distinct from bariatric revision surgery and the 503A/503B compounded-GLP-1 channel.